Allos Therapeutics (ALTH)
Allos Therapeutics Revenue Growth: 4.33%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ALTH Revenue Growth Rankings
| Overall | 44th percentile | 2427 of 4358 |
| Sector | 37th percentile | 286 of 456 in Healthcare |
| Industry | 43rd percentile | 21 of 37 in Drug Manufacturers - Other |
ALTH Revenue Growth Range, Past 5 Years
| Minimum | 4.33% | Mar 2012 |
| Maximum | 336.6% | Jun 2011 |
| Average | 100.2% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ALTH related companies
ALTH News
$SPPI Earnings were great in Q1, and forward outlook is also positive for Fusilev, deal for $ALTH is closing soon, so Folotyn is on the way.
about 2 days ago by Glopolon
about 2 days ago by Glopolon
Allos (ALTH) Sees Increased Volatility; FTC Requests More Info on Merger with Spectrum (SPPI)
May 10, 9:44AM Street Insider
May 10, 9:44AM Street Insider
RT @mitrado Deal between $ALTH & $SPPI concludes Mon.13th. Right? Will $SPPI stock price reflect that purchase? _More importantly Short% WOW
about 18 days ago by Glopolon
about 18 days ago by Glopolon
The deal between $ALTH and $SPPI is concluded on Monday, the 13th. Right? Will $SPPI stock price reflect that purchase?
about 18 days ago by mitrado
about 18 days ago by mitrado
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.
May 01, 6:57PM Business Wire
May 01, 6:57PM Business Wire
Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN® in Europe
Apr 20, 9:54AM Business Wire
Apr 20, 9:54AM Business Wire
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Apr 16, 8:15AM Business Wire
Apr 16, 8:15AM Business Wire
Brean Murray Carret & Co. Downgrades Allos Therapeutics (ALTH) to Hold; Adding More Color To Spectrum (SPPI)
Apr 10, 7:10AM Street Insider
Apr 10, 7:10AM Street Insider
$SPPI and $ALTH match made in heaven. ALTH candidates work well with SPPI sales and manufacturing. SPPI robbed the bank
about 52 days ago by BrianNichols
about 52 days ago by BrianNichols
$ALTH lt-value within $SPPI a lot higher than 1.82; Apaziquone is definitely not done, expect FDA with open ears on combined study results
about 52 days ago by OysterX
about 52 days ago by OysterX
RT @Street_Insider Spectrum Pharmaceuticals $SPPI to Acquire Allos Therapeutics $ALTH for $1.82/sh in cash plus one Contingent Value Right
about 52 days ago by StockTwits
about 52 days ago by StockTwits
Shares of Allos Therapeutics $ALTH, Spectrum Pharma $SPPI to resume trading at 7:30am ET
about 52 days ago by Street_Insider
about 52 days ago by Street_Insider
Spectrum Pharmaceuticals $SPPI to Acquire Allos Therapeutics $ALTH for $1.82 per share in cash plus one Contingent Value Right
about 52 days ago by Street_Insider
about 52 days ago by Street_Insider
URGENT: $ALTH filed to delay releasing annual earnings results (SEC Filing Form NT 10K) http://stks.co/2t6E
about 73 days ago by MarketBrief
about 73 days ago by MarketBrief
$ALTH forms bullish "Diamond Bottom" chart pattern. http://stks.co/2rha via @RecogniaEvents
about 73 days ago by WallStJesus
about 73 days ago by WallStJesus
$ALTH forms bullish "Diamond Bottom" chart pattern. http://stks.co/2rf3
about 74 days ago by RecogniaEvents
about 74 days ago by RecogniaEvents
Listen to $ALTH Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2hM2
about 82 days ago by earningscast
about 82 days ago by earningscast
$ALTH Reports Q4 FOLOTYN Net Product Sales of $15.4 Million; 17% Increase from Q3 2011
about 138 days ago by Benzinga
about 138 days ago by Benzinga
$ALTH http://stks.co/1nOq Biotech name coming out of a range. Watch the $1.47 level.
about 143 days ago by VexTrades
about 143 days ago by VexTrades
$ALTH Nice small "cup-and-handle" reversal pattern is forming. http://chart.ly/4akpg6a
about 143 days ago by BuyOnStrength
about 143 days ago by BuyOnStrength
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALTH | 1.80 | +0.00 | +0.00% | 192.53M |
| ALTE | 22.72 | -0.28 | -1.22% | 2.292B |
| ALT | 48.95 | -0.07 | -0.14% | |
| ALSK | 1.85 | +0.00 | +0.00% | 83.86M |
| ALR | 18.62 | +0.05 | +0.27% | 1.495B |
| ALOT | 8.00 | +0.00 | +0.00% | 59.20M |
| ALOG | 65.24 | -0.82 | -1.24% | 797.89M |
| ALO | 11.69 | +0.00 | +0.00% | |
| ALNY | 10.43 | +0.00 | +0.00% | 540.59M |
| ALN | 1.25 | -0.04 | -3.10% | 43.09M |